pdf   xlsx method abbreviations

la/mBC - HER2 positive, ... , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) (extension) 0.85 [0.49, 1.47]< 10%1 study (1/-)72.0 %NAnot evaluable important-
events or deaths (EFS) (extended) 0.98 [0.64, 1.51]< 10%1 study (1/-)53.7 %NAnot evaluable non important-
pCR 0.78 [0.47, 1.30]> 10%1 study (1/-)17.1 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.